Takeda's GP40 agonist drug lowers blood sugar in type 2 diabetes without hypoglycemia risk. PDF Print
Medical News: These data, which were presented at the American Diabetes Association 71st Annual Scientific Sessions, demonstrated that the GPR40 agonist, at doses ranging from 6.25 to 200 mg a day, met its primary endpoint of statistically significantly lowering HbA1c (blood glucose) levels over a 12-week period versus placebo. This was achieved without significant increase in the incidence of hypoglycemia (low blood sugar) compared to placebo.

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.